Human immunodeficiency virus type 1 envelope messenger RNA (HIV-1 env mRNA)

Human immunodeficiency virus type 1 envelope messenger RNA (HIV-1 env mRNA) is the viral transcript responsible for the synthesis of the gp160 precursor protein, which is essential for the formation of the viral envelope and subsequent host cell entry (Cullen, B. R., 2003, J. Cell Sci.). The env mRNA is characterized by the presence of the Rev-Response Element (RRE), a complex secondary structure that mediates the nuclear export of the transcript via interaction with the viral Rev protein. As a therapeutic target, HIV-1 env mRNA offers multiple points of intervention, including the use of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to trigger transcript degradation or inhibit translation (Rossi, J. J., 2006, Biotechniques). Furthermore, small molecule inhibitors or ribozymes like OZ1 can target specific sequences within the env transcript to prevent the production of infectious progeny (Mitsuyasu, R. T., et al., 2009, Nature Medicine). While targeting the env mRNA provides a mechanism to bypass traditional protein-based resistance, the high genetic diversity and rapid mutation rate of the HIV-1 envelope region pose significant challenges for maintaining long-term therapeutic efficacy. Current research focuses on utilizing RNA-based therapies and gene editing tools to achieve sustained viral suppression or contribute to a functional cure.

Other names

HIV-1 env transcriptHIV-1 gp160 mRNAHIV-1 envelope glycoprotein mRNAHIV-1 env RNA

Inhibition of translation through antisense binding, RNA interference-mediated degradation, or disruption of Rev-mediated nuclear export via the Rev-Response Element (RRE).